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216Objective: In cardiac cell therapy almost every cell type tested experimentally has yielded some benefit.
However, there is a lack of studies directly comparing the function of various stem/progenitor cell populations.
This study describes the expansion of peripheral blood CD133þ cells and compares their functional properties
with those of other commonly used human progenitor cell populations.
Methods: CD133þ cells were generated from the CD133 fraction of peripheral blood, either serially (pooled–
derived) or after 14 days of culture (derived). Their phenotypic, migratory, and vasculogenic properties were com-
pared with those of 4 commonly used progenitor cell populations in vitro.
Results: Serial expansion resulted in an 11-fold increase in the number of CD133þ cells. The proportion of
derived CD133þcells collected between 0 and 8 days also expressing CD34 and vascular endothelial growth fac-
tor receptor 2 was similar (approximately 60%, P¼ .41). Adherent, 4-day cultured endothelial progenitor cells
demonstrated enhanced migration compared with each of the other 5 cell populations (all P  .002). The migra-
tion of derived CD133þprogenitors was enhanced by coculture with CD133cells or their supernatant (P<.05).
In vitro vasculogenesis assays revealed that derived and pooled–derived CD133þcells had superior vasculogenic
potential compared with other progenitor populations (P  .03).
Conclusions: A novel source of expandable CD133þcells can be generated from the CD133 fraction of periph-
eral blood. The CD133 phenotypic marker translates into the cell being vasculogenically more potent in vitro,
which could be beneficial to inducing vasculogenesis in the ischemic heart. Furthermore, intercellular interactions
appear important for improving the therapeutic efficacy of cell transplantation. (J Thorac Cardiovasc Surg
2010;140:216-24)Supplemental material is available online.
Cardiac cell–based therapies, one of the major areas of trans-
lational research in which cardiac surgeons play a key role,
involve the delivery of stem/progenitor cells to areas of the
ischemic tissue and infarcted myocardium to stimulate and
accelerate the processes of vasculogenesis, myogenesis, or
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The Journal of Thoracic and Cardiovascular Surgplanted into the hearts of experimental animals or patients
with coronary artery disease (CAD), and almost every cell
type tested has yielded some degree of benefit experimen-
tally. However, clinical benefits have been modest. Today,
there remain major hurdles in cell expansion, delivery,
adhesion, local amplification, vascularization, and func-
tional incorporation (Figure 1).
One issue that needs to be addressed is the identification
of the ‘‘ideal’’ stem/progenitor cell population for optimal
vasculogenesis considering how important the paracrine/hu-
moral mechanism might be.2 In clinical use autologous cells
from the blood, bone marrow (BM), or other tissues are
favored because they circumvent the potential problems
associated with ethics, availability, and immune responses.
Several heterogeneous and preselected progenitor cell pop-
ulations derived from BM or peripheral blood (PB) mononu-
clear cells (MNCs), such as mesenchymal stem cells
(MSCs), endothelial progenitor cells (EPCs), or circulating
progenitor cells, have been used in various experimental
and clinical settings.3-6 One cell population of interest for
therapeutic vasculogenesis in the ischemic or infarcted myo-
cardium is the MSC. Transplanting MSCs into the heart has
been shown to improve its perfusion and function.3 Another
cell population, the circulating progenitor cells, which in-
clude EPCs, can home to injured tissues and are importantery c July 2010
Abbreviations and Acronyms
BM ¼ bone marrow
CAD ¼ coronary artery disease
EBM-2 ¼ endothelial basal medium 2
EPC ¼ endothelial progenitor cell
GRO ¼ growth-related oncogene
HUVEC ¼ human umbilical vein endothelial cell
IL ¼ interleukin
MCP ¼ monocyte chemoattractant protein
MNC ¼ mononuclear cell
MSC ¼ mesenchymal stem cell
PB ¼ peripheral blood
RANTES ¼ regulated upon activation, normal
T-cell expressed and secreted
VEGF ¼ vascular endothelial growth factor
VEGFR-2 ¼ vascular endothelial growth factor
receptor 2
Zhang et al Evolving Technology/Basic Sciencefor vascular repair and maintenance.3,6 A variety of cell
sources, isolation methods, and culture conditions have
been used to produce mainly heterogeneous populations of
EPCs for transplantation. One commonly used ex vivo ex-
pansion technique yields 4- to 7-day adherent EPCs from
the culture of circulating PB-MNCs on fibronectin.6
Preselection to obtain more specific subpopulations of
EPCs can be performed, involving an isolation of cells based
on markers, such as CD34, vascular endothelial growth
factor receptor 2 (VEGFR-2), and/or CD133.7 CD34 and
VEGFR-2 are both expressed at lower levels on mature en-
dothelial cells, whereas CD133, also known as prominin or
AC133, is expressed on hematopoietic stem cells but isCardiac stem
Cell expansion 
Cell delivery 
Cell survival 
and retention 
Intravenous: too few to the 
target
Intracoronary: unsuitable for 
larger cells, may exacerbate 
atherosclerosis
Intramyocardial: invasive, 
less suitable in AMI
Many cell types 
have little capacity 
to proliferate 
>90% of delivered 
cells rapidly fade
away from the 
target
Ex-Vivo and Delivery Hurdles   
FIGURE 1. Hurdles in cardiac cell therap
The Journal of Thoracic and Caabsent on mature endothelial cells and monocytic cells.
Although CD133 might be a more specific marker of stem/
progenitor cells and might provide a clinical benefit,8 its
functional role in cell biology remains uncertain.
Recently, the PB became a preferred cell source for regen-
erative therapy considering its noninvasiveness and easyavail-
ability. However, the frequency of CD133þCD34þVEGFR-2þ
cells in total PB-MNCs is very low (approximately 0.002%).9
Although some research showed that granulocyte colony-
stimulating factor–mobilized blood from patients contains
5- to 100-fold higher levels of MSCs and EPCs compared
with nonmobilized blood,10 the ability of these cells to im-
prove cardiac remodeling and function after acute myocardial
infarction (AMI) has been disappointing.11
Consequently, one first step for clinical stem cell therapy
would be to obtain large amounts of homogenous and well-
characterized cells and study them. In this regard we identi-
fied a new subpopulation of EPCs, termed ‘‘derived’’
CD133þ PB cells.12 These cells demonstrated improved
adhesion and ability to form capillary-like structures in vitro
compared with freshly isolated CD133þprogenitors from the
PB.
Many studies have examined the efficacy of different
progenitor cell populations individually; however, direct
functional studies that compare several cell populations are
lacking. Additionally, intercellular interactions can have
a significant effect on the functional activity of progenitor
populations both in vitro and in vivo,3,12 and further elucida-
tion of these interactions and cytokine influence might
benefit the optimization of cell therapy strategies. Therefore
assessing the vasculogenic properties and interactions of
different EPCandBMpopulationsmight be invaluable to op-
timize clinical cell-based therapeutic vasculogenesis. This
study was designed to (1) investigate methods of CD133þ cell therapy 
Vascularization
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TABLE 1. Patients’ characteristics
All patients (n¼ 12)
Aortic valve
disease (n¼ 6)
Mitral valve disease
(n¼ 5)
Aortic and mitral valve
disease (n¼ 1)
Age (y) 64.7 10.7 65.7 8.3 61.0 13.0 79
Male/female sex (n) 10/2 5/1 5/0 0/1
CAD (n) 0 0 0 0
Diabetes (n) 0 0 0 0
CHF (n) 2 (17%) 1 1 0
Hypertension (n) 5 (42%) 3 1 1
Hypercholesterolemia (n) 5 (42%) 2 2 1
Smoking (n) 4 (33%) 2 2 0
CAD, Coronary artery disease; CHF, congestive heart failure.
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SPB cell expansion, (2) characterize derived CD133þPB cells
and the influence of intercellular interactions on their func-
tion, and (3) evaluate their vasculogenic and migratory prop-
erties in comparison with other commonly used human
progenitor populations from the PB and BM.Cell types
Derived CD133+ cells Pool-derived CD133+ cells
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FIGURE 2. A, The number of pooled–derived CD133þ cells (derived se-
rially) was significantly greater than that of derived CD133þ cells (after
14 days of culture). *P<.05 versus fresh CD133þcells; ^P<.05 versus de-
rived CD133þcells. B, The presence of a peripheral blood mononuclear cell
(PB-MNC) supernatant or CD133þ cells (from whole PB-MNCs) inhibited
the generation of CD133þ cells from the CD133 fraction compared with
normal expansion conditions (Control). *P< .003 versus control.MATERIALS AND METHODS
Cell Isolation and Expansion
This study was approved by the Human Research Ethics Board of the
University of Ottawa Heart Institute. After acquiring informed consent
from human patient donors undergoing valve surgery (n¼ 12) without
concomitant CAD or diabetes (to limit interpatient variability in progenitor
cell function), both PB and sternal BM were harvested immediately after
sternotomy. Details of patients’ characteristics are found in Table 1.
Overall, 6 different populations of stem/progenitor cells were obtained
from PB or BM, as described in the online supplemental Materials and
Methods section: (1) fresh CD133þPB cells, (2) derived CD133þPB cells,
(3) pooled–derived CD133þ PB cells, (4) ‘‘classical’’ EPCs, (5) fresh
CD133þBM cells, and (6) MSCs. Cell counts and viability were determined
by using a cell counter (Beckman Coulter, Mississauga, Ontario, Canada).
Briefly, to obtain derived CD133þPB cells from CD133fractions, 2 dif-
ferent protocols were used. Cells in protocol 1 had fresh media added every
3 days without aspiration of the old media. After 14 days, both adherent and
nonadherent cells were collected and separated to obtain derived CD133þ
PB cells. In protocol 2 the nonadherent population was removed every 2
days over a period of 8 days, separated to collect the CD133þcells, and cry-
opreserved. After 8 days, cryopreserved cells were combined to constitute
the pooled–derived CD133þ population. Cell phenotype was analyzed by
using flow cytometry (FACSAria cell sorting system; BD Biosciences,
San Jose, Calif). Details are provided in the online supplemental Materials
and Methods section.
Investigation of CD133þCell Generation
Freshly isolated CD133PB cells were cultured to determine possible in-
hibitory mechanisms on the generation of CD133þcells under the following
conditions: (1) supernatant from whole PB-MNCs, (2) fresh CD133þ PB
cells, and (3) supplemented endothelial basal medium 2 (EBM-2 [control];
Clonetics, Guelph, Canada). After 48 hours of exposure, the adherent and
nonadherent cells from each condition were lifted and separated to obtain
theCD133þcells, and the numbers of derivedCD133þcellswere determined.
In Vitro Migration Assay
Each of the 6 cell populations were labeled with CellTracker Orange
(Molecular Probes, Eugene, Ore), and then 23 104 labeled cells of each
type were placed separately in the upper chamber with EBM-2 without
VEGF.13 The lower chamber contained serum-free media with 50 ng/mL218 The Journal of Thoracic and Cardiovascular Surgvascular endothelial growth factor (VEGF; Sigma, Oakville, Canada). After
24 hours of incubation, cells migrated into the lower chamber were counted
manually from 6 random high-powered fields.ery c July 2010
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FIGURE 3. A, The average number per field of view of migrating cells for the 6 progenitor populations. *P< .001 versus all other cell populations. PB,
Peripheral blood; BM, bone marrow; EPC, endothelial progenitor cell; MSC, mesenchymal stem cell. B, The number per high-powered field of migrating
CD133þcells (fresh or derived) with CD133cells or its supernatant after 24hours of culture. *P .005 versus CD133þcells alone; ^P<.05 versus incubation
with CD133cells. C, Relative expression of selected cytokines and growth factors (normalized to control values for each cytokine). *P<.005 versus control
media; ^P< .05 versus supernatant of fresh CD133þ peripheral blood cells; #P< .05 versus supernatant of derived CD133þ peripheral blood cells. GRO,
Growth-related oncogene; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; MIP-1beta, macrophage inflammatory protein 1b; RANTES, regu-
lated upon activation normal T cell expressed and secreted; NAP-2, neutrophil-activating protein 2.
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Fractions
The cell groups were as follows: (1) fresh CD133þ PB, (2) derived
CD133þPB, (3) fresh CD133þPB combined with fresh CD133PB, (4) de-
rived CD133þ PB combined with fresh CD133 PB, (5) fresh CD133þ PB
with the CD133 supernatant, and (6) derived CD133þ PB with the
CD133 supernatant. Cell migratory potential was assessed according to
the methods described previously.12 Before and after culture, flow cytomet-
ric analysis was performed to determine the expression of VEGFR-2 on
CD133þ cells in the first 4 groups.
Cytokine Antibody Array
We sought to determine the cytokines present in the supernatants of var-
ious cell populations after 24 hours of culture with the human cytokine an-
tibody array V (RayBiotech, Norcross, Ga). The cell populations examinedThe Journal of Thoracic and Cawere as follows: (1) fresh CD133þPB, (2) derived CD133þPB, and (3) fresh
CD133 PB. Supplemented EBM-2 was used as a control, and the differ-
ences in the level of each growth factor and cytokine were quantified against
internal controls within the array and then compared between cell
populations as fold changes. Kodak 1D Imaging software (Kodak, Roches-
ter,NY)was used to determine the intensities of cytokine spots on each array.
In Vitro Vasculogenesis Assay
Labeled cells (13 104) of each population were seeded onto solidified
ECMatrix (Chemicon, Temecula, Calif), with 13 104 human umbilical
vein endothelial cells (HUVECs) as supporting cells. HUVECs alone
were used as a control. After 24 hours of incubation, 6 random high-pow-
ered fields were taken for each cell type. The complete area of tubules
formed, total tube length, and percentage contribution to the total area of
capillaries were determined.rdiovascular Surgery c Volume 140, Number 1 219
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Data are presented as the mean  standard error of the mean. Statistical
analyses were performed with SigmaStat 3.1.1 (SigmaStat, Richmond,
Calif). Comparisons of data between groups were performed with
a 1-way analysis of variance, with Bonferroni corrections as appropriate.RESULTS
Expansion of PB CD133þProgenitors
The number of CD133þ cells was expanded by culturing
the CD133PB fraction according to 2 protocols (Figure 2,
A). With protocol 1, the culture of CD133 cells for 14
days resulted in derived CD133þ cells (0.32 0.103 106),
which is equivalent to a 3.09 1.37–fold increase compared
with the number of CD133þ cells in the fresh PB-MNC iso-
late (0.12 0.033 106, P< .05). With protocol 2, after 8
days, the number of generated CD133þ cells in the pooled–
derived population (1.21 0.223 106) was 11-fold greater
than that obtained from the freshly isolated PB-MNCs
(0.14 0.033 106, P< .05). Also, the number of CD133þ
cells generated in the pooled–derived groupwas significantly
greater than that in the 14-day derived group (P< .05). Ex-
pression of CD34 and VEGFR-2 on CD133þ cells obtained
was examined by means of flow cytometry (see Figure E1,
A). On day 0, the proportion of circulating CD133þ cells
also expressing CD34 and VEGFR-2 was 39.5%  9.3%.
For days 2, 4, 6, and 8, the percentages were 67.6% 
9.5%, 56.2%  14.5%, 58.0%  8.9%, and 69.4% 
15.1%, respectively (see Figure 1, B; P¼ .41), suggesting
that similar cell populations were being generated every
2 days.Potential Mechanisms Involved in CD133þ
Generation
Fresh CD133PB cells were cultured under 3 conditions
to investigate a potential mechanism involved in the gener-
ation of CD133þcells. The results showed that generation of
CD133þ cells was significantly inhibited by the presence of
CD133þ cells and by whole PB-MNC culture supernatant
(P< .003; Figure 2, B). When exposed to CD133þ cells,
only 71.7%  7.7% derived CD133þ cells were obtained
relative to control numbers (100%). Similarly, exposure of
CD133 cells to PB-MNC supernatant resulted in only
49.4%  9.2% generation of derived CD133þ cells
compared with control numbers.FIGURE 4. A–H, Representative images of the contribution of progenitor cel
endothelial cells (HUVECs): A, HUVECs alone (control); B, fresh CD133þ per
‘‘classical’’ endothelial progenitor cells (EPCs); E, BM mesenchymal stem cell
PB cells; and H, pooled–derived CD133þ PB cells. Scale bar¼ 150 mm. I, Ave
cell populations. Derived and pooled–derived CD133þPB cells had significantl
.007), MSCs from BM (^P< .001), and control HUVECs (#P< .05). J, Derive
significantly greater complete tube length formation compared with control values
CD133þprogenitors had the greatest physical contribution compared with all gro
pooled–derived CD133þPB cells.
The Journal of Thoracic and CaMigratory Potential of Various Progenitor Cell
Populations
The VEGF-induced migration potential of 6 cell popula-
tions was tested (see Figure E2, A–F). The number of
migrating cells per field of view was not significantly
different between fresh CD133þ PB cells (5.29 0.53)
and CD133þ BM cells (7.04 1.06), MSCs (4.23 0.79),
derived CD133þPB cells (3.63 0.46), and pooled–derived
CD133þPB cells (5.58 0.59, P¼ .9). However, all popu-
lations had significantly lower migration compared with
‘‘classical’’ EPCs (61.09 19.57) from PB (P  .002;
Figure 3, A).
Cell Interaction Effects onMigration of CD133þCells
Fresh and derived CD133þ cells were cultured with
CD133cells or their supernatant to improve CD133+ cells’
migratory potential (Figure 3, B, and see Figure E2, G–I).
When combined with CD133 cells, the number of migrat-
ing cells per field of view for both fresh (26.87 1.52)
and derived (19.67 1.84) CD133þ populations signifi-
cantly increased when compared with the cells plated alone
(5.69 0.31 and 3.66 0.24, respectively; P< .05). Simi-
larly, the addition of the supernatant of CD133cells also in-
creased the number of migrating fresh CD133þ cells
(29.63 2.56). For the derived CD133þ cells, when com-
bined with the supernatant of CD133 cells, the number of
migrating cells (30.33 1.93) was significantly increased
compared with the number of derived CD133þ cells com-
bined with the CD133 cells themselves (P< .05).
At the time of isolation, 59.89% 6.41% of fresh CD133þ
cells expressed VEGFR-2, and after 24 hours of culture alone,
expression decreased significantly to 48.72%  8.37%
(P¼ .04). When the fresh CD133þ cells were cultured with
CD133 cells, VEGFR-2 expression increased significantly
to 74.92%  4.36% (P¼ .04). However, for derived
CD133þ cells, VEGFR-2 expression before culture was
95.88%  1.32% and did not significantly change whether
cells were cultured alone (98.18%  0.74%) or with
CD133 cells (98.20%  0.96%, see Figure E3, A).
Cytokines and Growth Factors Released by CD133
Cells
The supernatant of cultured CD133 cells was shown to
have increased levels of different cytokines and growthls (red) to the formation of capillary structures with human umbilical vein
ipheral blood (PB) cells; C, fresh CD133þ bone marrow (BM) cells; D, PB
s (MSCs); F, BM-MSCs with DAPI-stained HUVECs; G, derived CD133þ
rage complete area of tubule structure formation with different progenitor
y greater capillary formation compared with fresh CD133þ from PB (*P 
d and pooled–derived CD133þ progenitors and fresh CD133þPB cells had
. *P<.01 versus control;-P<.001 versus all cell populations. K, Derived
ups except the pooled–derived CD133þcells.-P<.001 versus derived and
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control given in parentheses) growth-related oncogene
(GRO; 4.7); interleukin (IL) 1b (2.6); IL-6 (38.0); IL-8
(23.1); IL-10 (8.9); monocyte chemoattractant protein
(MCP) 1 (12.4); macrophage inflammatory protein (MIP)
1b (3.5); regulated upon activation, normal T-cell expressed
and secreted (RANTES; 3.1); and neutrophil-activating pro-
tein (NAP) 2 (3.0). The release of GRO, IL-6, IL-8, IL-10,
and MCP-1 by CD133 cells was also significantly greater
than their release from cultured fresh and derived CD133þ
PB progenitor cells after 24 hours (Figure 3, C).
Comparison of Vasculogenic Potential of Progenitor
Populations
In vitro vasculogenesis assays on all 6 cell populations
(Figure 4, A–H) revealed that derived CD133þ cells
(0.31 0.02 mm2) and pooled–derived CD133þ cells
(0.32 0.04 mm2) significantly enhanced the complete
area of tubules formed compared with control cells (P<
.03), whereas MSCs (0.002 0.00 mm2) significantly de-
creased capillary formation (P¼ .01; Figure 4, I). Total
tube length was also calculated for each cell type, revealing
that derived CD133þ cells (9.37 1.15 mm), pooled–de-
rived CD133þ cells (9.89 0.91 mm), and fresh CD133þ
PB cells (9.04 0.79 mm) had significantly enhanced
capillary tube length compared with control cells (P< .01;
Figure 4, J). The presence of MSCs from the BM
(0.19 0.06 mm) created an environment that significantly
inhibited the ability of HUVECs to form extended capillaries
(P< .001). The derived CD133þ cells (22.84%  3.26%)
and the pooled–derived CD133þ cells (18.90%  2.53%)
had significantly greater physical contribution to the total
area of capillaries compared with the other groups (P<
.001; Figure 4, K).
DISCUSSION
Preclinical and early clinical trials have suggested that
transplantation of progenitor cells has the potential to im-
prove the function of an ischemic or infarcted myocardial
territory.3-6,8,14,15 However, it still remains unknown which
cell source or cell type is optimal for vascular regeneration
and myocardial functional restoration. It will be crucial to
elucidate the basic biology and characterization of specific
populations and compare them with respect to their func-
tional properties to optimize significant clinical benefits. In
this regard the current study demonstrated the successful ex-
pansion of human CD133þPB progenitors, which appear to
be of superior vasculogenic potential for myocardial cell
therapies based on in vitro comparison studies.
Previous studies showed that autologous CD133þcells en-
hanced myocardial perfusion and global function.8,15,16
However, the frequency of CD133þprogenitors in the blood
and BM is low, and their mechanism and function in thera-
peutic vasculogenesis or cell therapy remain unclear. In this222 The Journal of Thoracic and Cardiovascular Surgstudy we examined CD133þcells to better characterize these
progenitors and also expanded their number for increased
relevance for cell-based therapy. A nearly 11-fold expansion
of pooled–derived CD133þPB cells was achieved by means
of serial removal of the nonadherent CD133þ cells every 2
days over a period of 8 days generated from culture of the
CD133 fraction of PB-MNCs. These cells also expressed
CD34 and VEGFR-2 (56.2% to 69.4%), suggesting that
serial expansion generated progenitor cells similar to circu-
lating CD133þCD34þVEGFR-2þ EPCs.7 To a lesser extent
(3-fold expansion), CD133þCD34þVEGFR-2þ cells were
also derived from the culture of CD133 cells after a 2-
week period. Our data indicate that the reduced cell expan-
sion observed with this protocol likely resulted from the
inhibitory effects of other CD133þ cells in the culture.
Specifically, CD133þ cell generation was significantly
inhibited by the presence of whole PB-MNC supernatant
or CD133þ cells, suggesting that the removal of CD133þ
cells creates an environment conducive to CD133þ cell
generation. Conversely, direct contact with CD133þ cells,
the release of cytokines/soluble factors from these cells,
or both might inhibit CD133þgeneration through paracrine
mechanisms.
Direct comparison of the derived CD133þ cells with sev-
eral commonly used progenitors showed that the ‘‘classi-
cal’’ EPC population had the greatest migratory potential
response to VEGF. ‘‘Classical’’ EPCs consist of a heteroge-
neous mix of cells, including those of monocytic, hemato-
poietic, and endothelial lineage, and their greater
migratory potential might be related to interactions between
cell populations.17 Notably, it was observed that migration
was enhanced for both fresh and derived CD133þ PB
progenitors when combined with CD133 cells or their
supernatant. VEGFR-2 expression on these cells was also in-
vestigated to try to explain this improved migration because
VEGF was the chemotactic agent used. For fresh CD133þ
cells, VEGFR-2 expression was increased significantly
when incubated with CD133 cells. However, for derived
CD133þ cells, the expression of VEGFR-2 (already at ap-
proximately 96%) was not significantly changed after cocul-
ture with CD133 cells. This can partly explain the greater
improvement in migration for fresh CD133þ PB cells com-
pared with that of derived CD133þ PB cells. Therefore one
important mechanism by which interaction with CD133
cells might improve migration of the CD133þ progenitor
cells is increased VEGFR-2 expression.
Because CD133þ cell migration was significantly in-
creased by coculture with the CD133 cell supernatant, it
is likely that paracrine effects through the secretion of cyto-
kines and chemokines are involved in regulating cell func-
tion. The CD133 supernatant expressed increased levels
of GRO, IL-1b, IL-6, IL-8, IL-10, MCP-1, MIP 1b,
RANTES, and NAP-2 compared with control values. There-
fore provision of cytokines and growth factors from otherery c July 2010
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the migratory capacity of CD133þprogenitor cells. In addi-
tion, recent evidence suggests that neovascularization/vas-
culogenesis of the dysfunctional myocardium from
paracrine and humoral factors and secondary recruitment
of host cells are the likely mechanisms leading to functional
improvement in patients with CAD.19,20
This study also revealed that derived CD133þ cells are
functionally more potent than several other select progenitor
cells with respect to their vasculogenic potential in vitro.
Overall, the derived CD133þcells demonstrated significantly
greater contribution to forming capillary-like structures in
vitro (incorporation, total capillary area, and length). The
capacity of freshly isolated CD133þCD34þVEGFR-2þ cells
to yield endothelial cells has recently been questioned.18
However, the greater direct incorporation of derived
CD133þ progenitor cells into capillary-like structures ob-
served in this study suggests that these cells might have
improved endothelial differentiation. It is possible that inter-
cellular interaction between different cell types is required
for optimal function of the CD133þCD34þVEGFR-2þpopu-
lation, a consideration not explored in the previous study. Al-
ternatively, greater paracrine effects of derived CD133þcells
on the HUVECs is suggested by the greater total capillary
area and length seen with the addition of derived CD133þ
cells compared with the other progenitor populations.
Interestingly, the 2 cell populations from the BM differed
in their in vitro vasculogenic potential: the fresh CD133þ
fraction contributed to capillary-like formation, whereas
the cultured MSCs did not. Although these are in vitro re-
sults, this is consistent with recent evidence demonstrating
that different cell populations from the BM differ in their
vasculogenic potential.21 Also, it has been demonstrated
that without prior environmental conditioning or differenti-
ation into endothelial cells, the ability of MSCs to contribute
to capillary-like structures in Matrigel is compromised.22 It
was shown that the ability of the BM population to contrib-
ute in vasculogenesis was associated with the positive
expression of the endothelial cell-surface markers CD34,
VEGFR-2, and/or CD31.22
However, the limitations of this study need to be acknowl-
edged. First, all functional evaluations and comparisons
were performed in in vitro assays. Nevertheless, previous
studies have reported that similar results were obtained in
in vitro migration and vasculogenesis assays versus in
vivo studies.23,24
Second, in this study only VEGF-induced migration capa-
bility was assessed. Several chemokines and growth factors
have been shown to be responsible for stem cell homing and
migration to the myocardium, such as VEGF, stromal cell–
derived factor 1, MCP-3, hepatocyte growth factor, fibro-
blast growth factor 2, and insulin-like growth factor 1. These
different factors recruit and regulate different stem cell
populations. VEGF is a potent and highly specific mitogenThe Journal of Thoracic and Cafor EPCs, and previous data indicate that VEGF overexpres-
sion improves EPC migratory, adhesive, and proliferative
capabilities both in vitro and in vivo.25
To our knowledge, this is the first study to directly com-
pare the functional properties of 5 commonly used progeni-
tor cell populations in simple in vitro experiments in an
effort to elucidate the vasculogenic potential of these cells.
Derived CD133þ cells appear to be a superior source of
vasculogenic cells for transplantation based on this study.
Also, interactions (cytokine/paracrine mechanism) between
cell populations in vitro were observed to improve the mi-
gratory function of CD133þ progenitor cells, which might
have implications for clinical applications as well. Therefore
derived CD133þ PB cells merit further investigation as po-
tentially more effective and potent endothelial progenitors
for cardiac cell–based therapy. Interactions between cell
populations also require further attention to improve current
cell-based vasculogenic therapies. An optimal cell popula-
tion for cell-based vasculogenic treatment might exist that
is likely a combination of different subtypes that can aug-
ment/participate in vasculogenesis, that require interaction
with the host cells for maximal therapeutic effect, or both.
In conclusion, despite heightened expectations, the bene-
fits of cell-based cardiac therapy have not yet been estab-
lished in patients. The field must remain willing to return
to the laboratory to improve our mechanistic understanding
and refine our therapeutic approaches. The present study,
albeit in vitro, attempted to perform this by comparing dif-
ferent cell populations for the first time, by investigating
cell–cell and cell-soluble factor interactions, and by testing
a method to expand a rare progenitor identified as being
more vasculogenically potent than other commonly used
cell populations.References
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MATERIALS AND METHODS
Isolation of CD133þCells From PB
Total PB-MNCs were freshly isolated from the blood of
human donors by using Histopaque1077 (Sigma) density-
gradient centrifugation of buffy coats. On the initial day of
PB-MNC isolation, CD133þ cells were separated from
PB-MNCs by using CD133microbeads and a magnetically
activated cell sorter (autoMACS; Miltenyi Biotech, Ber-
gisch–Gladbach, Germany), thereby providing day 0 (fresh)
CD133þ cells and CD133PB cells.
Expansion of CD133þCells From CD133PB
Fractions
CD133 fractions were plated on fibronectin-coated,
12-well culture plates (Becton Dickinson, Mississauga,
Canada) at a density of 13 106 cells/cm2 in EBM-2
supplemented with EGM-2-MV-SingleQuots (Clonetics)
containing 5% fetal bovine serum, 50 ng/mL human
VEGF, 50 ng/mL human insulin-like growth factor 1,
and 50 ng/mL human epidermal growth factor. Two dif-
ferent protocols were used to obtain derived CD133þ PB
cells. Cells in protocol 1 had fresh media added to the
wells every 3 days without aspiration of the old media.
After 14 days, both adherent and nonadherent cells were
collected and separated by means of autoMACS to obtain
derived CD133þ PB cells. In protocol 2 the nonadherent
population was removed every 2 days over a period of
8 days and separated with the autoMACS machine to col-
lect CD133þ cells. The generated CD133þ cells were cry-
opreserved in 1-mL aliquots with 10% dimethyl sulfoxide
in complete media. After 8 days, cryopreserved cells from
days 0, 2, 4, 6 and 8 were thawed and combined to con-
stitute the pooled–derived CD133þ population (hereafter
referred to as pooled–derived CD133þ PB cells).
Isolation of EPCs
Briefly, total human PB-MNCs were cultured in supple-
mented EBM-2 media on fibronectin-coated tissue-culture
plates (13 106 MNCs/cm2) for 4 days. The adherent cells,
hereafter referred to as ‘‘classical’’ EPCs, were then
collected.
Isolation of CD133þCells and MSCs From BM
Donormarrowwas aspirated from the sternumwith a stan-
dard marrow aspiration needle and washed in Hanks bal-
anced salt solution (Gibco Invitrogen, Burlington, Canada)
to obtain BM cells. Bone marrow was digested completely
with collagenase type I (250 U/mL, Gibco Invitrogen), and
the cell suspension was filtered with a 70-mm nylon cell
strainer (Becton Dickinson). Isolated BM-MNCs were sep-
arated from the CD133 fraction by means of autoMACS
to obtain day 0 (fresh) CD133þ BM cells. The filtered cell
suspension was washed and plated at 1.33 106 cells/cm2
in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum (Gibco Invitrogen), 2 mmol/
L L-glutamine (Sigma), and 100 U/mL penicillin/streptomy-
cin (Gibco Invitrogen) to obtain ex vivo expanded MSCs.
After 4 days, the nonadherent cells were removed. The
media was replaced every 3 days for 2 weeks or until the
adherent MSC population was 80% to 90% confluent.
The phenotype of theMSC population was characteristically
CD29þCD44þCD45 (data not shown).
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FIGURE E1. Cell expansion. A, Representative flow cytometric analysis for coexpression of CD34 and vascular endothelial growth factor receptor 2
(VEGFR-2) on fresh and serially derived CD133þ cells collected every 2 days for a period of 8 days. PE, Phycoerythrin; FITC, fluorescein isothiocyanate.
B, Flow cytometric results showing the percentage of CD133þ cells also expressing CD34 and VEGFR-2 over 8 days. C, Cumulative number of generated
CD133þ cells removed every 2 days from the serial culture of the CD133 fraction of peripheral blood mononuclear cells. *P< .001 for day 8 versus other
times.
Evolving Technology/Basic Science Zhang et al
224.e2 The Journal of Thoracic and Cardiovascular Surgery c July 2010
E
T
/B
S
FIGURE E2. Cell migration. A–F, The migration properties of 6 cell populations. Representative migration assay images of fresh CD133þperipheral blood
(PB) cells (A), fresh CD133þbone marrow (BM) cells (B), PB ‘‘classical’’ endothelial progenitor cells (C), BMmesenchymal stem cells (D), derived CD133þ
PB cells (E), and pooled–derived CD133þ PB cells (F) are shown. G–I, Cell interaction effects on CD133þ cell migration. Representative migration assay
images of derived CD133þ cells alone (G), derived CD133þ cells with CD133 cells (H), and derived CD133þ cells with CD133 cell supernatant (I) after
24 hours of culture are shown. Scale bar¼ 75 mm.
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FIGURE E3. Mechanisms involved in the migration improvement by cell
interactions. A, Expression of vascular endothelial growth factor receptor 2
(VEGFR-2) on fresh or derived CD133þ cells cultured with or without
CD133cells for 24 hours. *P<.05. B–F, Representative cytokine/growth
factor array images of cytokine/growth factor map of array membrane (B),
culture medium only (C), CD133 peripheral blood (PB) cell supernatant
after 24 hours of incubation (D), fresh CD133þ PB cell supernatant after
24 hours of incubation (E), and derived CD133þPB cell supernatant (F) after
24 hours of incubation are shown. Pos, Positive; Neg, negative; ENA-78,
epithelial cell–derived neutrophil-activating protein-78;GCSF, granulocyte
colony-stimulating factor; GM-CSF, granulocyte–macrophage colony-
stimulating factor;GRO, growth-related oncogene; I-309, a small glycopro-
tein secreted by activated T-cells; IL, interleukin; IFN, interferon; MCP,
monocyte chemoattractant protein;MCSF, macrophage colony-stimulating
factor;MDC, macrophage-derived chemokine;MIG, monokine induced by
gamma interferon;MIP, macrophage inflammatory protein; RANTES, regu-
lated upon activation normal T cell expressed and secreted; SCF, stem cell
factor; SDF, stromal cell–derived factor; TARC, thymus and activation-reg-
ulated chemokine; TGF, transforming growth factor; TNF, tumor necrosis
factor; EGF, epidermal growth factor; IGF, insulin-like growth factor;
VEGF, vascular endothelial growth factor; PDGF, platelet-derived growth
factor; BDNF, brain-derived neurotrophic factor; BLC, B-lymphocyte
chemoattractant; FGF, fibroblast growth factor; GCP, granulocyte chemo-
tactic protein; GDNF, glial cell line–derived neurotrophic factor; HGF, he-
patocyte growth factor; IGFBP, insulin-like growth factor–binding protein;
IP-10, interferon-inducible protein 10; LIF, leukemia inhibitory factor;
LIGHT, lymphotoxin-related inducible ligand that competes for glycopro-
tein D binding to herpes virus entry mediator on T-cells; MIF, macrophage
migration inhibitory factor; NAP, neutrophil-activating protein; NT, neuro-
trophic factor; PARC, pulmonary and activation-regulated chemokine;
PIGF, placental growth factor; TIMP, tissue inhibitor of metalloproteinases.
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